HCPLive Five - Dermatology Updates at EADV Congress 2025

A wide array of dermatologists and clinical experts from across the globe gathered in Paris, France, for the 2025 European Academy of Dermatology and Venereology (EADV) Congress, a significant conference in the dermatology space. The meeting highlighted a wide spectrum of updates spanning inflammatory skin disease, hair disorders, and chronic conditions such as psoriasis and atopic dermatitis, while also spotlighting late-breaking data on novel investigational drugs.

There were many different scientific sessions, industry symposia, and late-breaking data presentations, allowing for many insights at EADV 2025 into clinical practice, therapeutic innovation, and long-term disease management. The HCPLive team was on-site covering the conference, interviewing investigators, and working to highlight the most relevant findings for frontline dermatology care. In this edition of the 'HCPLive Five' series, the team spotlights 5 key interviews with leading experts sharing their perspectives on pivotal trial data and evolving treatment strategies from the meeting floor:

Emerging Therapeutic Options for Alopecia Areata in Adolescents, With Brittany Craiglow, MD

Brittany G. Craiglow, MD, spoke with HCPLive about her EADV session titled ‘The Current and Emerging Therapeutic Landscape for Treating AA in Adolescents.’ Craiglow, an assistant professor, adjunct dermatology at Yale School of Medicine, touched on takeaways from her session regarding alopecia areata treatments among adolescents. She was also asked how clinicians should approach conversations with colleagues who may be hesitant to implement JAK inhibitors or other systemic options for younger individuals.

Discussing New Ritlecitinib Findings in Cicatricial Alopecia, With Anusha Pasumarthi, MD

Anusha Pasumarthi, MD, MSc, a second-year dermatology resident at Mount Sinai, interviewed at EADV regarding new findings suggesting ritlecitinib therapy resulted in favorable safety data and rapid improvements in cicatricial alopecia clinical scores, supporting the use of JAK3/TEC inhibition for this set of conditions. Pasumarthi highlighted several important points about the findings on ritlecitinib and their significance for cicatricial alopecia.

Cardiovascular Risk and Upadacitinib Treatment for Atopic Dermatitis, With Christopher Bunick, MD, PhD

In another interview at EADV, Christopher G. Bunick, MD, PhD, highlighted his team’s recent data suggesting that individuals with moderate-to-severe atopic dermatitis treated with upadacitinib for up to 6 years have low rates of venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and malignancy, excluding nonmelanoma skin cancer (exNMSC), compared to others who also have this condition and regardless of previous cardiovascular risk status.

Discussing Phase 2b Findings on Temtokibart for Atopic Dermatitis, With Chih-ho Hong, MD, FRCPC

Chih-ho Hong, MD, FRCPC, a Vancouver dermatologist and trial investigator on this phase 2b randomized, double-blind trial, spoke in an EADV interview on his team’s findings on temtokibart. In these late-breaking data, the use of this investigational monoclonal antibody targeting the interleukin (IL)-22RA1 receptor subunit was associated with significant improvements in various measures of patients’ disease severity and activity for atopic dermatitis biomarkers.

Discussing Icotrokinra’s Performance Versus Deucravacitinib in Psoriasis, With Linda Stein Gold, MD

This interview at EADV featured Linda Stein Gold, MD, the director of dermatology clinical research for the Henry Ford Health System, who spoke on her team’s 24-week findings on icotrokina for patients with psoriasis. These data resulted from the phase 3 ICONIC-ADVANCE 1 and 2 studies, showing that icotrokinra demonstrated superior responses versus those treated with placebo and with deucravacitinib in the treatment of moderate-to-severe plaque psoriasis.